Volume 30, Number 6—June 2024
Research
Follow-Up Study of Effectiveness of 23-Valent Pneumococcal Polysaccharide Vaccine Against All-Type and Serotype-Specific Invasive Pneumococcal Disease, Denmark
Katrine Finderup Nielsen1
, Lise Birk Nielsen1, Tine Dalby, Frederikke Kristensen Lomholt, Hans-Christian Slotved, Kurt Fuursted, Zitta Barrella Harboe, Charlotte Sværke Jørgensen, and Palle Valentiner-Branth
, Lise Birk Nielsen1, Tine Dalby, Frederikke Kristensen Lomholt, Hans-Christian Slotved, Kurt Fuursted, Zitta Barrella Harboe, Charlotte Sværke Jørgensen, and Palle Valentiner-Branth
Table 2
Effectiveness of PPSV23 vaccine against IPD compared with no vaccination in follow-up study, Denmark, April 22, 2020–March 15, 2023*
| IPD type | Vaccination status | No. events | Person-years | VE, % (95% CI) |
|
|---|---|---|---|---|---|
| Unadjusted | Adjusted† | ||||
| All | Unvaccinated | 200 | 1,277,147 | Referent | |
| Vaccinated |
313 |
1,919,841 |
26 (11–39) |
32 (18–44) |
|
| PPSV23 serotype | Unvaccinated | 134 | 1,277,147 | Referent | |
| Vaccinated |
186 |
1,919,841 |
36 (19–49) |
41 (25–53) |
|
| PPSV23 serotype excluding serotype 3 | Unvaccinated | 105 | 1,277,147 | Referent | |
| Vaccinated |
102 |
1,919,841 |
54 (38–65) |
58 (43–68) |
|
| Serotype 3 | Unvaccinated | 29 | 1,277,147 | Referent | |
| Vaccinated |
84 |
1,919,841 |
−25 (−95 to 20) |
−17 (−83 to 25) |
|
| Serotype 8 | Unvaccinated | 32 | 1,277,147 | Referent | |
| Vaccinated |
27 |
1,919,841 |
56 (27–74) |
62 (36–77) |
|
| Serotype 22F | Unvaccinated | 25 | 1,277,147 | Referent | |
| Vaccinated |
9 |
1,919,841 |
86 (70–94) |
88 (75–95) |
|
| PPSV23 non-PCV15 serotype‡ |
Unvaccinated | 67 | 1,277,147 | Referent | |
| Vaccinated |
71 |
1,919,841 |
45 (21–61) |
50 (28–65) |
|
| PPSV23 non-PCV20 serotype§ | Unvaccinated | 18 | 1,277,147 | Referent | |
| Vaccinated | 14 | 1,919,841 | 57 (2–81) | 61 (10–83) | |
*IPD, invasive pneumococcal disease; PCV15, 15-valent pneumococcal conjugate vaccine; PCV20, 20-valent pneumococcal conjugate vaccine; PPSV23, 23-valent polysaccharide pneumococcal vaccine; VE, vaccine effectiveness. †Adjusted for age and comorbidities as a restricted cubic spline and sex as a categorical variable. ‡Serotypes 8, 10A, 11A, 12F, 15B, 2, 9N, 17F, and 20. §Serotypes 2, 9N, 17F, and 20.
1These authors contributed equally to this article.
Page created: April 10, 2024
Page updated: May 22, 2024
Page reviewed: May 22, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
Content Credential